Abstract LB-18: Statins use prevents ovarian cancer recurrence in women with diabetes mellitus.

Abstract

Background: Low-density lipoproteins levels are significant predictors of clinical outcomes in ovarian cancer (OvCa) patients. Despite American Diabetes Association (ADA) guidelines, suboptimal hyperlipidemia management is reported in women diagnosed with both OvCa and diabetes mellitus (DM). This study evaluated the impact of cholesterol drugs utilization and importance of following ADA guidelines on OvCa recurrence and survival. Methods: All DM patients newly diagnosed with OvCa between 2003 and 2010 at Roswell Park Cancer Institute were retrospectively reviewed (n=482). A total of 60 newly diagnosed OvCa patients having a form of diabetes at the time of cancer diagnosis were identified. Out of these, 14 patients were excluded due to presence of type 1 diabetes (n=6) or prior cancer history (n=8). The remaining 46 patients were included in the final analyses. Tumor pathology, outcomes, baseline co-morbidities and self-reported drug therapy were documented. Follow-up began at cancer diagnosis and ended with first confirmed recurrence and/or death. Cases lost to follow-up were censored at the date of last contact. To analyze categorical outcomes across different treatment groups, Fisher's exact test was used. All multivariate analyses were done using Cox proportional hazards models while accounting for age, weight, stage, histology, and cumulative comorbidity. A nominal significance level of 0.05 was used in all testing. Results: Average age at diagnosis and body mass index in this data set was 70±10 years and 34.76±7.07 kg/m2, respectively. Over three quarters of this population was diagnosed with advanced stage OvCa and 96% had a tumor grade of 2 or higher. Roughly two thirds of the tumors evaluated had a serous histology. Out of the cases reviewed, 52% did not receive any form of cholesterol management and 46% received a statin alone or in combination. After a median follow-up of 26.9 months, patients receiving statin monotherapy for cholesterol management were found to have improved recurrence (HR=0.17, 95% CI: 0.04 to 0.73, P=0.02); however, no impact on overall mortality was noted as compared to patients not receiving any cholesterol management medication. Conclusions: This study explored for the first time the association between statin utilization and prognosis in OvCa patients with DM. Given the identified benefit, reinforcing compliance with DM guidelines for hyperlipidemia management in OvCa patients deserves further attention. Our findings seed the beginning of a novel approach in personalized OvCa care. Citation Format: Michelle E. Amsler, Kristina A. Chmiel, Olesya Yaremko, Clare Carroll, Jingjing Yin, Terry Mashtare, Anthony Miliotto, Rachel Brightwell, Kunle Odunsi, Alice C. Ceacareanu. Statins use prevents ovarian cancer recurrence in women with diabetes mellitus. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-18. doi:10.1158/1538-7445.AM2013-LB-18

Effects of statins on cancer mortality and progression: A systematic review and meta‐analysis of 95 cohorts including 1,111,407 individuals

“…After removing 156 studies, a total of 95 studies met the inclusion criteria and were included in the final analysis (Fig. and Supporting Information Table S2) …”

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

“…Two of the 11 studies were published only in abstract form [35, 39]. The studies were all published between 2008 and 2016.…”

“…While no association was found between statin use and RFS (HR 0.66, 95% CI, 0.40 to 1.08) in one study [38], statin users had significantly improved RFS (HR 0.17, 95% CI, 0.04 to 0.73) in the other study [35]. Two studies compared the survival outcomes of statin users and statin non-users in a hyperlipidemic cohort [33, 36].…”

“…A total of 11 non-randomized studies involving more than 6,920 patients with endocrine-related gynecologic cancers were included in the meta-analysis, with 10 cohort studies [ 29 , 31 – 39 ] and 1 case-control study [ 30 ]. Two of the 11 studies were published only in abstract form [ 35 , 39 ]. The studies were all published between 2008 and 2016.…”

“…As the effect of statin use on RFS was only evaluated in two studies involving 189 patients with ovarian cancer [ 35 , 38 ], a meta-analysis was not performed for RFS. While no association was found between statin use and RFS (HR 0.66, 95% CI, 0.40 to 1.08) in one study [ 38 ], statin users had significantly improved RFS (HR 0.17, 95% CI, 0.04 to 0.73) in the other study [ 35 ]. Two studies compared the survival outcomes of statin users and statin non-users in a hyperlipidemic cohort [ 33 , 36 ].…”